Blood Urea Nitrogen as a Predictor of In-Hospital Mortality in Acute Coronary Syndrome Patients

Wasyanto, Trisulo; Tridamayanti, Annisa

doi:10.26911/theijmed.2019.04.03.07

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pada pasien dengan gagal jantung, kadar urea yang tinggi merupakan penanda kematian yang kuat dibandingkan kreatinin. 8 Tingginya kadar urea darah pada penelitian ini berkorelasi dengan penurunan fraksi ejeksi ventrikel kiri pada pasien STEMI (r = -0,241, p=0,001). Terdapat 103 (60%) pasien dalam penelitian ini mengalami penurunan fraksi ejeksi ventrikel kiri (kurang dari 50%).…”

Section: Bahasanunclassified

Relationship between Blood Urea Level and Left Ventricular Ejection Fraction (LVEF) in Patients with ST-Elevation Myocardial Infarction

Djafar

Luntungan

Panda

et al. 2022

eCL

View full text Add to dashboard Cite

Lower left ventricular ejection fraction (LVEF) is associated with greater mortality among patients with ST-elevation myocardial infarction (STEMI). Renal dysfunction is considered to worsen the prognosis of STEMI patients. This study aimed to determine the correlation between blood urea level and left ventricular ejection fraction in patients with STEMI. This was a descriptive and analytical study using the Spearman’s rho test. Correlation was significant at the 0.05 level. Data were collected from iSTEMI Registry database of patients admitted in Prof. Dr. R. D. Kandou General Hospital from October 3rd, 2018 to July 28th, 2019. The results obtained 172 STEMI patients with the mean age of 59.47±9.92 years old, and most were male (77.3%). The median blood urea level was 37 mg/dL (IQR 16) whereas a mean ejection fraction was 46.43%±10.43. The Spearman’s rho test showed that higher blood urea level was significantly associated with lower left ventricular ejection fraction (p=0.01; r=-0.241). In conclusion, higher blood urea level is associated with decreased left ventricular ejection fraction in patients with ST-elevation myocardial infarctionKeywords: blood urea level; left ventricular ejection fraction; STEMI Abstrak: Fraksi ejeksi ventrikel kiri yang menurun dikaitkan dengan tingginya mortalitas pada penderita infark miokard akut (IMA) dengan elevasi segmen ST (STEMI). Disfungsi renal diketahui memperburuk prognosis penderita IMA-EST. Penelitian ini bertujuan untuk meng-evaluasi korelasi antara kadar ureum darah dengan fraksi ejeksi ventrikel kiri pada penderita STEMI. Jenis penelitian ialah deskriptif analitik menggunakan data registri iSTEMI penderita STEMI yang dirawat di RSUP Prof. Dr. R. D. Kandou dari 3 Oktober 2018 hingga 28 Juli 2019. Penyajian deskriptif dan korelasi bivariat Spearman rho dilakukan untuk menganalisis hubungan kadar ureum darah dan fraksi ejeksi ventrikel kiri. Hasil penelitian mendapatkan 172 penderita STEMI dengan usia rerata 59,47±9,92 tahun; mayoritas ialah laki-laki (77,3%); median kadar urea darah ialah 37 mg/dL (rentang interkuartil 16); dan rerata fraksi ejeksi ialah 46,43%±10,43. Hasil uji Spearman rho menunjukkan bahwa peningkatan kadar urea darah secara bermakna berhubungan dengan fraksi ejeksi ventrikel kiri yang menurun (p=0,01; r=-0,241). Simpulan penelitian ini ialah peningkatan kadar urea darah berhubungan dengan menurunnya fraksi ejeksi ventrikel kiri pada penderita STEMI.Kata kunci: kadar urea darah; fraksi ejeksi ventrikel kiri; STEMI

show abstract

Section: Bahasanunclassified

Relationship between Blood Urea Level and Left Ventricular Ejection Fraction (LVEF) in Patients with ST-Elevation Myocardial Infarction

Djafar

Luntungan

Panda

et al. 2022

eCL

View full text Add to dashboard Cite

show abstract

“… 6 According to data from Public General Hospital Dr. Moewardi Surakarta, the death rate due to AMI from 2014 to 2018 is still very high, at 15.9%. 7 Therefore, we should be able to anticipate outcomes in patients with AMI to ensure that the proper course of action can be taken. This study aimed to prove that cystatin C is a predictor of major adverse cardiovascular events (MACE) after PCI in patients with AMI without cardiogenic shock and renal impairment within 6 months of observation.…”

Section: Introductionmentioning

confidence: 99%

Cystatin C as a Predictor of Major Adverse Cardiovascular Event in Patients with Acute Myocardial Infarction Without Cardiogenic Shock and Renal Impairment After Coronary Intervention

Wasyanto,

Yasa,

Yudhistira

2023

IJGM

Self Cite

View full text Add to dashboard Cite

Purpose To prove that cystatin C is a predictor of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI), either with ST-segment Elevation (AMI-EST) or without ST-segment elevation (AMI-NEST), without cardiogenic shock or renal impairment. Patient and Methods This was an observational cohort study. Samples were obtained from AMI patients who underwent PCI between February 2022 and March 2022 at the Intensive Cardiovascular Care Unit. Cystatin C levels were measured before PCI. MACE were observed within 6 months. Comparisons between normally distributed continuous data were performed using the t -test; Mann–Whitney test was used for non-normally distributed data. Categorical data were compared using the chi-squared test. The cut-off point of cystatin C levels to predict MACE was analyzed using Receiver Operating Characteristics (ROC). Results The participants were 40 AMI patients, consisting of 32 patients (80%) with AMI-EST and eight patients (20%) diagnosed with AMI-NEST, who were evaluated for the occurrence of MACE within 6 months after PCI. Ten patients (25%) developed MACE during follow-up [(MACE (+)], and the rest were in the MACE (-) group. Cystatin C levels were significantly higher in the MACE (+) group (p=0.021). ROC analysis revealed a cystatin C level of 1.21 mg/dL; cystatin C > 1.21 is associated with MACE risk, showing a significant relationship with the odds ratio value reaching 26.00, with 95% CI (3.99–169.24). Conclusion Cystatin C level is an independent predictor of MACE in patients with AMI without cardiogenic shock or renal impairment after PCI.

show abstract

“…During hospitalization, 228 (15.9%) patients died with the main causes of mortality being cardiogenic shock (59.9%) and ventricular arrhythmias (25%). 3 Inflammation is the key component in the process that causes atherosclerotic plaque rupture and myocardial injury in AMI. Measurement of inflammatory biomarkers will, therefore, be an attractive choice for improving the management of AMI patients.…”

Section: Introductionmentioning

confidence: 99%

The Roles of Pentraxin-3 to Predict In-Hospital and Three Months Major Adverse Cardiac Event in Acute Myocardial Infarction

Bestara

Wasyanto

Purwaningtyas

2020

Acta Cardiol Indones

Self Cite

View full text Add to dashboard Cite

Background: Pentraxin-3 (PTX3) was a useful marker for localized vascular inflammation and damage in the cardiovascular system. Recent studies have shown that plasma PTX3 is elevated in patients with myocardial infarction; however, its prognostic value still remains unclear. Aims: This study aimed to investigate the relationship between PTX3 and in-hospital and three months of a major adverse cardiac event (MACE) in acute ST-elevation and non-ST-elevation myocardial infarction patients. Methods: This cohort study conducted from September 1st, 2018 to October 31st, 2019 in Dr. Moewardi Hospital. A 144 patient were observed during hospitalization and 130 survived patient were follow up for three months. The admission PTX3 was compared between the patient with and without MACE. Higher levels of PTX3 were defined as concentrations greater than the optimal cut-off value derived from the Receiver Operating Characteristic (ROC) curve. Results: Among patients, 43.75% was anterior STEMI, 35.42% was inferior STEMI, and 20.38% was NSTEMI with median PTX3 level was 8.16 (0.21-69.35) ng/mL. The in-hospital MACE occurred in 52% of patients, while three months of MACE occurred in 17% patient. Patients with MACE had a higher level of PTX3 compared without MACE (p<0.001) during hospitalization, but not in three months follow up (p=0.408). Multivariate analysis also shown PTX3 was as a predictor of in-hospital MACE (OR 1.127; p=0.001), along with heart rate (OR 1.025; p=0.015). There are different of in-hospital MACE between the patient with high (≥8.247 ng/mL) and low (<8.225 ng/mL) PTX3 level with a hazard ratio (HR) 2.142 (95%CI 1.315-3.487; p=0.002), but the result did not similar after three months follow up (p=0.373). Conclusion: The PTX3 can be used as a predictor of in-hospital MACE but not for three months follow up.

show abstract

Blood Urea Nitrogen as a Predictor of In-Hospital Mortality in Acute Coronary Syndrome Patients

Cited by 4 publications

References 0 publications

Relationship between Blood Urea Level and Left Ventricular Ejection Fraction (LVEF) in Patients with ST-Elevation Myocardial Infarction

Relationship between Blood Urea Level and Left Ventricular Ejection Fraction (LVEF) in Patients with ST-Elevation Myocardial Infarction

Cystatin C as a Predictor of Major Adverse Cardiovascular Event in Patients with Acute Myocardial Infarction Without Cardiogenic Shock and Renal Impairment After Coronary Intervention

The Roles of Pentraxin-3 to Predict In-Hospital and Three Months Major Adverse Cardiac Event in Acute Myocardial Infarction

Contact Info

Product

Resources

About